Rituximab Plus Lenalidomide for Patients With Relapsed / Refractory Indolent Non-Hodgkin's Lymphoma (Follicular Lymphoma and Marginal Zone Lymphoma)

Clinical trial NCT01938001 · COMPLETED

Trial details

NCT number: NCT01938001
Sponsor: Celgene
Status: COMPLETED
Phase: Phase 3
Study type: INTERVENTIONAL

Lymphoma, Non-Hodgkin

Start date: 2013-11-21
Primary completion: 2018-06-22
Enrollment: 358

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.